Language:
  
[Sign in] [Register]   

EIAab logo

Index > Protein center > PIK3CA(Gene name) > Human
  • Add your favorite
  • PIK3CA (Gene name),
  • Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (Protein name ),  PK3CA_HUMAN from NCBI database.
  • top
  • Come back to page head.
  • |
  • General Annotation
  • |
  • Antigen Annotation
  • |
  • 3D
  • |
  • Predicted Eptitope
  • |
  • Vaild Sequence
  • |
  • Related Databases
  • |
  • Feedback
  • Gene name:
    PIK3CA;
    Protein name:
    Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform(PI3-kinase subunit alpha;PI3K-alpha;PI3Kalpha;PtdIns-3-kinase subunit alpha);
    Alternative:
    Phosphoinositide-3-kinase catalytic alpha polypeptide;Phosphatidylinositol-4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha(PtdIns-3-kinase subunit p110-alpha;p110alpha);2.7.11.1;Serine/threonine protein kinase PIK3CA);
    Organism:
    Human (Homo sapiens). 
    General Annotation
    Sub Unit:
    Heterodimer of a catalytic subunit PIK3CA and a p85 regulatory subunit (PIK3R1, PIK3R2 or PIK3R3). Interacts with IRS1 in nuclear extracts. Interacts with RUFY3 (By similarity). Interacts with RASD2 (By similarity). Interacts with APPL1. Interacts with HRAS1 and KRAS (By similarity). Interaction with HRAS1/KRAS is required for PI3K pathway signaling and cell proliferation stimulated by EGF and FGF2.
    Function:
    Phosphoinositide-3-kinase (PI3K) that phosphorylates PtdIns (Phosphatidylinositol), PtdIns4P (Phosphatidylinositol 4-phosphate) and PtdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol-3,4,5-triphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Participates in cellular signaling in response to various growth factors. Involved in the activation of AKT1 upon stimulation by receptor tyrosine kinases ligands such as EGF, insulin, IGF1, VEGFA and PDGF. Involved in signaling via insulin-receptor substrate (IRS) proteins. Essential in endothelial cell migration during vascular development through VEGFA signaling, possibly by regulating RhoA activity. Required for lymphatic vasculature development, possibly by binding to RAS and by activation by EGF and FGF2, but not by PDGF. Regulates invadopodia formation in breast cancer cells through the PDPK1-AKT1 pathway. Participates in cardiomyogenesis in embryonic stem cells through a AKT1 pathway. Participates in vasculogenesis in embryonic stem cells through PDK1 and protein kinase C pathway. Has also serine-protein kinase activity: phosphorylates PIK3R1 (p85alpha regulatory subunit), EIF4EBP1 and HRAS.
    Subcellular Location:
    N/A
    Protein Attributes:
    Sequence length:
    1068
    Sequence:
    50:
    MPPRPSSGEL | WGIHLMPPRI | LVECLLPNGM | IVTLECLREA | TLITIKHELF | 
    100:
    KEARKYPLHQ | LLQDESSYIF | VSVTQEAERE | EFFDETRRLC | DLRLFQPFLK | 
    150:
    VIEPVGNREE | KILNREIGFA | IGMPVCEFDM | VKDPEVQDFR | RNILNVCKEA | 
    200:
    VDLRDLNSPH | SRAMYVYPPN | VESSPELPKH | IYNKLDKGQI | IVVIWVIVSP | 
    250:
    NNDKQKYTLK | INHDCVPEQV | IAEAIRKKTR | SMLLSSEQLK | LCVLEYQGKY | 
    300:
    ILKVCGCDEY | FLEKYPLSQY | KYIRSCIMLG | RMPNLMLMAK | ESLYSQLPMD | 
    350:
    CFTMPSYSRR | ISTATPYMNG | ETSTKSLWVI | NSALRIKILC | ATYVNVNIRD | 
    400:
    IDKIYVRTGI | YHGGEPLCDN | VNTQRVPCSN | PRWNEWLNYD | IYIPDLPRAA | 
    450:
    RLCLSICSVK | GRKGAKEEHC | PLAWGNINLF | DYTDTLVSGK | MALNLWPVPH | 
    500:
    GLEDLLNPIG | VTGSNPNKET | PCLELEFDWF | SSVVKFPDMS | VIEEHANWSV | 
    550:
    SREAGFSYSH | AGLSNRLARD | NELRENDKEQ | LKAISTRDPL | SEITEQEKDF | 
    600:
    LWSHRHYCVT | IPEILPKLLL | SVKWNSRDEV | AQMYCLVKDW | PPIKPEQAME | 
    650:
    LLDCNYPDPM | VRGFAVRCLE | KYLTDDKLSQ | YLIQLVQVLK | YEQYLDNLLV | 
    700:
    RFLLKKALTN | QRIGHFFFWH | LKSEMHNKTV | SQRFGLLLES | YCRACGMYLK | 
    750:
    HLNRQVEAME | KLINLTDILK | QEKKDETQKV | QMKFLVEQMR | RPDFMDALQG | 
    800:
    FLSPLNPAHQ | LGNLRLEECR | IMSSAKRPLW | LNWENPDIMS | ELLFQNNEII | 
    850:
    FKNGDDLRQD | MLTLQIIRIM | ENIWQNQGLD | LRMLPYGCLS | IGDCVGLIEV | 
    900:
    VRNSHTIMQI | QCKGGLKGAL | QFNSHTLHQW | LKDKNKGEIY | DAAIDLFTRS | 
    950:
    CAGYCVATFI | LGIGDRHNSN | IMVKDDGQLF | HIDFGHFLDH | KKKKFGYKRE | 
    1000:
    RVPFVLTQDF | LIVISKGAQE | CTKTREFERF | QEMCYKAYLA | IRQHANLFIN | 
    1050:
    LFSMMLGSGM | PELQSFDDIA | YIRKTLALDK | TEQEALEYFM | KQMNDAHHGG | 
    1068:
    WTTKMDWIFH | TIKQHALN
    3D Structure:
    N/A
    Predicted Eptitope:
    Please Sign in.
    EIAab Sequence  Vaild Sequence:
    Please Sign in.
    Related Databases
    UniGene:
    Pfam:
    MIM:
    SMR:
    KEGG:
    String:
    Uniprot:
     
    FOR
    ELISA Kit for Human PI3-kinase subunit alpha
    Cat.:
    E14307b
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    ELISA Kit for Human PI3-kinase subunit alpha
    Cat.:
    E14307h
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    ELISA Kit for Human PI3-kinase subunit alpha
    Cat.:
    E14307m
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    CLIA Kit for Human PI3-kinase subunit alpha
    Cat.:
    U14307m
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    CLIA Kit for Human PI3-kinase subunit alpha
    Cat.:
    U14307h
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    CLIA Kit for Human PI3-kinase subunit alpha
    MSDS:
    Please sign in first.
    Polyclonal Antibody for Human PI3-kinase subunit alpha
    Polyclonal Antibody for Human PI3-kinase subunit alpha
    Polyclonal Antibody for Human PI3-kinase subunit alpha
    Monoclonal Antibody for Human PI3-kinase subunit alpha
    Monoclonal Antibody for Human PI3-kinase subunit alpha
    Monoclonal Antibody for Human PI3-kinase subunit alpha
    Protein for Human PI3-kinase subunit alpha
    Protein for Human PI3-kinase subunit alpha
    Protein for Human PI3-kinase subunit alpha

    R&D Technical Data
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    Precision
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    Recovery
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    Linearity
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    References
    1. 1.
      "Molecular cloning, cDNA sequence, and chromosomal localization of the human phosphatidylinositol 3-kinase p110 alpha (PIK3CA) gene."
      Volinia S. , Hiles I. , Ormondroyd E. , Nizetic D. , Antonacci R. , Rocchi M. , Waterfield M.
      Genomics24:472-477(1994) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA];VARIANTS VAL-43 AND ARG-332
    2. 2.
      "Cloning and mutagenesis of the p110 alpha subunit of human phosphoinositide 3'-hydroxykinase."
      Stirdivant S.M. , Ahern J. , Conroy R.R. , Barnett S.F. , Ledder L.M. , Oliff A. , Heimbrook D.C.
      Bioorg. Med. Chem.5:65-74(1997) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA]
    3. 3.
      "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)."
      The MGC Project Team
      Genome Res.14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]
      tissue: Lung.
    4. 4.
      "Identification of a chromosome 3p14.3-21.1 gene, APPL, encoding an adaptor molecule that interacts with the oncoprotein-serine/threonine kinase AKT2."
      Mitsuuchi Y. , Johnson S.W. , Sonoda G. , Tanno S. , Golemis E.A. , Testa J.R.
      Oncogene18:4891-4898(1999) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: INTERACTION WITH APPL1
    5. 5.
      "Phosphoinositide 3-kinase signaling pathway mediated by p110{alpha} regulates invadopodia formation."
      Yamaguchi H. , Yoshida S. , Muroi E. , Yoshida N. , Kawamura M. , Kouchi Z. , Nakamura Y. , Sakai R. , Fukami K.
      J. Cell Biol.193:1275-1288(2011) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: FUNCTION IN INVADOPODIA FORMATION;CHARACTERIZATION OF VARIANTS LYS-545 AND ARG-1047
    6. 6.
      "Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha."
      Huang C.-H. , Mandelker D. , Gabelli S.B. , Amzel L.M.
      Cell Cycle7:1151-1156(2008) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: REVIEW ON CANCER
    7. 7.
      "Class I PI3K in oncogenic cellular transformation."
      Zhao L. , Vogt P.K.
      Oncogene27:5486-5496(2008) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: REVIEW ON FUNCTION;REVIEW ON CANCER
    8. 8.
      "Should individual PI3 kinase isoforms be targeted in cancer?"
      Jia S. , Roberts T.M. , Zhao J.J.
      Curr. Opin. Cell Biol.21:199-208(2009) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: REVIEW ON FUNCTION
    9. 9.
      "The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations."
      Huang C.-H. , Mandelker D. , Schmidt-Kittler O. , Samuels Y. , Velculescu V.E. , Kinzler K.W. , Vogelstein B. , Gabelli S.B. , Amzel L.M.
      Science318:1744-1748(2007) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (3 ANGSTROMS) IN A COMPLEX WITH PIK3R1;DOMAINS
    10. 10.
      "Solution structure of the C2 domain from human PI3-kinase p110 subunit alpha."
      RIKEN structural genomics initiative (RSGI)
      Submitted (2008-04) to the PDB data bank
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: STRUCTURE BY NMR OF 331-481
    11. 11.
      "A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane."
      Mandelker D. , Gabelli S.B. , Schmidt-Kittler O. , Zhu J. , Cheong I. , Huang C.H. , Kinzler K.W. , Vogelstein B. , Amzel L.M.
      Proc. Natl. Acad. Sci. U.S.A.106:16996-17001(2009) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF MUTANT HIS-1047 IN COMPLEX WITH WORTMANNIN AND PIK3R1;INTERACTION WITH PIK3R1;CHARACTERIZATION OF VARIANT ARG-1047;DOMAINS
    12. 12.
      "Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas."
      Broderick D.K. , Di C. , Parrett T.J. , Samuels Y.R. , Cummins J.M. , McLendon R.E. , Fults D.W. , Velculescu V.E. , Bigner D.D. , Yan H.
      Cancer Res.64:5048-5050(2004) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANTS CANCER LYS-542; LYS-545; PRO-546; ASN-1021; ARG-1047; LEU-1047 AND TYR-1065
    13. 13.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANTS CANCER GLY-545; LYS-545; LYS-546; GLU-546; ARG-1047 AND LEU-1047
    14. 14.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT CANCER ARG-1047
    15. 15.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANTS CANCER GLN-88; LYS-542; ALA-545 AND ASN-1025
    16. 16.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANTS CANCER LYS-542; LYS-545 AND ARG-1047
    17. 17.
      "Functional analysis of PIK3CA gene mutations in human colorectal cancer."
      Ikenoue T. , Kanai F. , Hikiba Y. , Obata T. , Tanaka Y. , Imamura J. , Ohta M. , Jazag A. , Guleng B. , Tateishi K. , Asaoka Y. , Matsumura M. , Kawabe T. , Omata M.
      Cancer Res.65:4562-4567(2005) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: CHARACTERIZATION OF VARIANTS CRC HIS-38; VAL-106; ARG-420; GLN-453; LYS-542; LYS-545; ILE-1043 AND ARG-1047
    18. 18.
      "High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma."
      Oda K. , Stokoe D. , Taketani Y. , McCormick F.
      Cancer Res.65:10669-10673(2005) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANTS CANCER GLN-542; LYS-542; GLY-545; LYS-545; ARG-1007; HIS-1021; CYS-1021; VAL-1035; ILE-1043; TYR-1047; ARG-1047; ASP-1050; LYS-1052 AND LEU-1065
    19. 19.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANTS CANCER LYS-542; GLY-545; LYS-545; GLN-1023; ARG-1047 AND LEU-1047
    20. 20.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANTS CANCER LYS-545 AND ARG-1047
    21. 21.
      "PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas."
      Lee J.W. , Soung Y.H. , Kim S.Y. , Lee H.W. , Park W.S. , Nam S.W. , Kim S.H. , Lee J.Y. , Yoo N.J. , Lee S.H.
      Oncogene24:1477-1480(2005) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT HCC ALA-545
    22. 22.
      "PIK3CA mutations in head and neck squamous cell carcinoma."
      Qiu W. , Schoenleben F. , Li X. , Ho D.J. , Close L.G. , Manolidis S. , Bennett B.P. , Su G.H.
      Clin. Cancer Res.12:1441-1446(2006) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANTS CANCER CYS-343; LYS-542; LYS-545 AND ARG-1047;VARIANT MET-391
    23. 23.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT CANCER ARG-1047
    24. 24.
      "PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma."
      Buttitta F. , Felicioni L. , Barassi F. , Martella C. , Paolizzi D. , Fresu G. , Salvatore S. , Cuccurullo F. , Mezzetti A. , Campani D. , Marchetti A.
      J. Pathol.208:350-355(2006) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANTS BC LYS-542; VAL-542; LYS-545; ARG-546; ARG-1047 AND LEU-1047
    25. 25.
      "Cancer-specific mutations in PIK3CA are oncogenic in vivo."
      Bader A.G. , Kang S. , Vogt P.K.
      Proc. Natl. Acad. Sci. U.S.A.103:1475-1479(2006) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: CHARACTERIZATION OF VARIANTS CANCER LYS-542; LYS-545 AND ARG-1047
    26. 26.
      "Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern."
      Hafner C. , Lopez-Knowles E. , Luis N.M. , Toll A. , Baselga E. , Fernandez-Casado A. , Hernandez S. , Ribe A. , Mentzel T. , Stoehr R. , Hofstaedter F. , Landthaler M. , Vogt T. , Pujol R.M. , Hartmann A. , Real F.X.
      Proc. Natl. Acad. Sci. U.S.A.104:13450-13454(2007) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANTS KERSEB LYS-542; LYS-545; GLY-545 AND ARG-1047
    27. 27.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANTS CLOVE ARG-420; LYS-542 AND ARG-1047
    28. 28.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANTS MCAP LYS-81; GLN-88; ARG-364; LYS-365; TYR-378; GLU-453 DEL; LYS-545; LYS-726; ARG-914; CYS-1021; ALA-1025; VAL-1035; ILE-1043; TYR-1047 AND SER-1049
    29. 29.
      "Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes."
      Orloff M.S. , He X. , Peterson C. , Chen F. , Chen J.L. , Mester J.L. , Eng C.
      Am. J. Hum. Genet.92:76-80(2013) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANTS CWS5 ASP-118; LYS-135; LYS-218; ILE-356; LYS-382 AND ALA-545
    Product Feedback Wall
    Hot Genes
    Atf2 ASPRO ACE ALCAM C19orf80 Trap1a KSR2 Gdf5
    Top Searches
    Ubiquitin-protein ligase metalloproteinase Ubiquitin ELISA Tumor necrosis Asprosin TRAP1A Alpha
    Why choose EIAAB
    Our products have been quoted by many publications in famous journals such as Cell; Cell Metabolism; Hepatology; Biomaterials.more
    Further Information
    About us Protein center Bank account Distributors Terms & Conditions Career eiaab.com.cn

    Copyright & copy www.eiaab.com2006-2016 All Rights Reserved    EIAab         Email:eiaab@eiaab.com

    Twitter